Campus Community

Campus Community

The Wellcome Genome Campus is home to some of the world’s foremost institutes and organisations in genomics and computational biology, committed to delivering life changing science with the reach, scale and imagination to solve some of humanity’s greatest challenges.

European Bioinformatics Institute (EMBL-EBI)

In addition to the Wellcome Sanger Institute, the Campus is also home to the European Bioinformatics Institute (EMBL-EBI).

The European Bioinformatics Institute (EMBL-EBI) help scientists realise the potential of ‘big data’ in biology, helping them exploit complex information to make discoveries that benefit mankind. They manage the world’s public biological data and make it freely available to the scientific community via a range of services and tools, perform basic research and provide professional training in bioinformatics.

The European Bioinformatics Institute is part of the European Molecular Biology Laboratory (EMBL), a non-profit, intergovernmental organisation funded by 21 member states and two associate member states. Their 570 staff represent 57 nationalities, and welcome a regular stream of visiting scientists throughout the year.

Elixir Technical Hub

ELIXIR is a pan-European infrastructure for the sharing of biological data, funded through sustainable contributions from national member states and the European Commission. The goal of ELIXIR is to orchestrate the collection, quality control and archiving of large amounts of biological data produced by life science experiments. Some of these datasets are highly specialised and would previously only have been available to researchers within the country in which they were generated.

ELIXIR Directorate and technical staff are based at the ELIXIR Technical Hub, alongside the European Bioinformatics Institute (EMBL-EBI) in a purpose-built facility that includes an Industry and Translation suite, offering space for collaboration with industry partners.

100,000 Genomes Project

The 100,000 Genomes Project will sequence genomes from around 70,000 National Health Service (NHS) patients, focusing on individuals with rare diseases or cancer. The project is managed by Genomics England, an organisation established by the Department of Health specifically for this purpose. Genomics England aims to bring benefit to patients, build capability in the burgeoning area of genomic medicine, and advance medical research. The sequencing operations for the 100,000 Genomes Project are based in a new, world-class sequencing hub on Campus.

Open Targets

For biomedical researchers who need to identify a biological target for a new therapy, Open Targets (previously known as the Centre for Therapeutic Target Validation (CTTV)) is a public-private initiative to transform drug discovery by enabling the systematic identification and prioritisation of targets. Open Targets combines large-scale genomic experiments with objective statistical and computational techniques to identify and validate the causal links between targets, pathways and diseases. Open Targets accelerates and enables research and innovation by making the evidence open and accessible to all.

Open Targets brings together expertise from four complementary organisations: GSK is a leading, global pharmaceutical company that has developed some of the most successful drugs of the past three decades; the European Bioinformatics Institute (EMBL-EBI) is a global leader in the management, integration and analysis of public domain life science data; the Wellcome Sanger Institute is a world-leading genomics institution with expertise in human genetics, cancer and infectious disease; and, Biogen, one of the world’s oldest independent biotechnology companies with leading multiple sclerosis and innovative hemophilia therapies.

Open Targets exists as a core operation within the Innovation Centre of the EBI South Building on the Wellcome Genome Campus and involves staff from each of the institutions directly interacting there with access to the full normal scientific life of the Campus. In addition it draws upon expertise from groups within the institutions spreading connections across the site.

To contact the team at Open Targets please email

The Centre for Global Pathogen Surveillance (cGPS)

The Centre for Global Pathogen Surveillance (cGPS) is a joint initiative between the Wellcome Sanger Institute and Imperial College London, focusing on the utility of pathogen whole genome sequencing for the global surveillance of disease. Initial aims are to produce and provide data for global public health use through intuitive applications which should enable decision making and monitoring of antimicrobial resistance, one of the greatest threats to public health that we face.

For further information please contact the cGPS Director David Aanensen

Biodata Innovation Centre

A new home for genomics and biodata companies is set to be established when the Campus opened the doors of its new Biodata Innovation Centre in July 2016. The Campus vision for the future focuses on translating scientific advances in the fields of genomics and bioinformatics into healthcare benefits. Supporting the delivery of our Campus vision, the new Biodata Innovation Centre enables complementary innovative genomic and biodata companies to join the Campus in delivering life-changing science with the reach, scale and imagination to solve some of humanities greatest challenges.

The Centre provides flexible space for innovative businesses that complement the unique research and science of the Campus Institutes. It provides accommodation in a range of unit sizes to suit individuals and early start-ups, through to larger, more established businesses. Wet lab space may be available for tenants in the future.

Businesses located in the new Innovation Centre will benefit from the array of existing campus amenities including parking and coach transport across the local area; catering, sports facilities and social activities; access to IT services; conferencing, exhibition and meeting room space; on-Campus accommodation for visitors and extensive award-winning grounds.

For an informal discussion on any aspect relating to the Biodata Innovation Centre, please contact Adrian Ibrahim, Head of Technology Transfer and Business Development.